Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients
Open Access
- 16 July 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 17 (20), 3144-3153
- https://doi.org/10.1093/hmg/ddn211
Abstract
Intraneuronal protein aggregates of the mutated huntingtin in Huntington's disease (HD) brains suggest an overload and/or dysfunction of the ubiquitin–proteasome system (UPS). There is a general inhibition of the UPS in many brain regions (cerebellum, cortex, substantia nigra and caudate-putamen) and skin fibroblasts from HD patients. In the current experiment, the widely used mutant huntingtin-exon 1 CAG repeat HD transgenic mice model (R6/2) (with 144 CAG repeat and exon 1) during late-stage pathology, had increases in proteasome activity in the striatum. However, this discrepancy with HD patient tissue was not apparent in the mutant CAG repeat huntingtin full-length HD (YAC72) transgenic mouse model during post-symptomatic and late-stage pathology, which then also showed UPS inhibition similar to HD patients' brains. In both types of HD model mice, we determined biochemical changes, including expression of brain-derived neurotrophic factor (BDNF) and mitochondrial complex II/III (MCII/III) activities related to HD pathology. We found increases of both BDNF expression, and MCII/III activities in YAC72 transgenic mice, and no change of BDNF expression in R6/2 mice. Our data show that extreme CAG repeat lengths in R6/2 mice is paradoxically associated with increased proteasome activity, probably as a cellular compensatory biochemical change in response to the underlying mutation. Changes in HD patients for UPS function, BDNF expression and MCII/III activity are only partially modeled in R6/2 and YAC72 mice, with the latter at 16 months of age being most congruent with the human disease.This publication has 56 references indexed in Scilit:
- Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtinThe Journal of cell biology, 2008
- Expanded-Polyglutamine Huntingtin Protein Suppresses the Secretion and Production of a Chemokine (CCL5/RANTES) by AstrocytesJournal of Neuroscience, 2008
- Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's diseaseJournal of Neuroinflammation, 2008
- Proteasome Activator Enhances Survival of Huntington's Disease Neuronal Model CellsPLOS ONE, 2007
- Mitochondrial dysfunction in Huntington’s disease: the bioenergetics of isolated and in situ mitochondria from transgenic miceJournal of Neurochemistry, 2007
- Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's diseaseNeurobiology of Disease, 2006
- Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brainEuropean Journal of Neuroscience, 2006
- Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseasesHuman Molecular Genetics, 2004
- Down-regulation of the Neurotrophin Receptor TrkB following Ligand BindingOnline Journal of Public Health Informatics, 2000
- Mitochondrial Impairment Reduces the Threshold for in Vivo NMDA-Mediated Neuronal Death in the StriatumExperimental Neurology, 1993